Although genomic and proteomic tools have been widely used to analyze GBM subtypes [5, 6], to map out specific mutations and signaling pathways [4], or to identify therapeutic targets related in particular to MET and EGFRvIII in combination [11], these approaches have not been used to interpret micro-environmental regulation. This evidence concerns the gene MET and glioblastoma.